Patents Assigned to POINT Biopharma Inc.
  • Radiopharmaceutical and methods
    Patent number: 11491246
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: November 8, 2022
    Assignee: POINT Biopharma, Inc.
    Inventor: Joe McCann
  • Radiopharmaceutical and methods
    Patent number: 11129912
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 28, 2021
    Assignee: POINT Biopharma Inc.
    Inventor: Joe McCann